Platelet Rich Plasma for Uterine Scar

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Jan 25, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Platelet Rich Plasma (PRP) to help women who have had cesarean deliveries and may face complications like uterine bleeding, pelvic pain, or irregular menstrual cycles. PRP is made from a small sample of the patient’s blood and is rich in special proteins that can help with healing. The goal is to see if using PRP can reduce problems related to scarring from cesarean sections.

To be eligible for this trial, women must be planning to have an elective cesarean delivery, be at least 37 weeks pregnant, and have a single baby. However, some women won’t be able to participate, such as those with certain blood conditions or previous uterine surgeries. If you join the trial, you can expect to receive this new treatment and contribute to important research that could improve care for future mothers. Keep in mind that the trial is not yet recruiting participants, so more information will be available once it starts.

Gender

FEMALE

Eligibility criteria

• Inclusion criteria:
• • Women undergoing elective cesarean delivery
• • Term pregnancy (≥37 weeks of gestation)
• • Singleton pregnancy
• Exclusion criteria:
• • Thrombocytopenia (CBC Platelet count \<70,000)
• • Connective tissue disease
• • Uterine scars other than cesarean (s/p myomectomy, s/p cornual resection)
• • Malformed uterus (unicornuate, bicornuate, didelphic)